Emerging evidence has linked the quantity of TRM cells, mostly CD103+CD8+TRM (referred to by “TRM” in this study unless otherwise noted), to better response to immunotherapy and better prognosis of patients with lung cancer [7–9]. Here, CD8A is linked to lung cancer.